von Niederhäusern W, Boillat J J, Petrescu D, Groppi W, Fanfani A, Mandelli V
Urol Res. 1983;11(4):181-5. doi: 10.1007/BF00256368.
Of 30 patients with severe, complicated U.T.I. 27 have been given single daily doses of Kelfiprim (KP), a new sulfatrimethoprim combination, for 8 weeks. In 24 bacteriuria was lastingly controlled, one had a relapse, one had a reinfection, and in one, with bladder carcinoma, bacteriuria persisted. Three other patients received KP for shorter periods, as they presented gastric intolerance or skin hypersensitivity, but in two of them a lasting sterilization of the urine has been obtained. The usefulness of a single daily dose schedule is stressed.
在30例患有严重复杂性尿路感染的患者中，27例患者每日单次服用新的磺胺甲恶唑复方制剂凯尔普林（KP），疗程为8周。其中24例患者的菌尿症得到了持久控制，1例复发，1例再次感染，1例患有膀胱癌，菌尿症持续存在。另外3例患者因出现胃部不耐受或皮肤过敏而接受了较短疗程的KP治疗，但其中2例患者的尿液实现了持久无菌。强调了每日单次给药方案的有效性。
